C1orf50_AU022252 Inhibitors
C1orf50_AU022252 Inhibitors are a collection of compounds that exert their effects through various pathways to reduce the functional activity of C1orf50_AU022252. Compounds such as Staurosporine and Sorafenib inhibit a wide range of protein kinases, which can lead to the downstream diminishment of C1orf50_AU022252 activity if it relies on kinase-mediated signaling for its function. Kinase inhibitors like Gefitinib, Imatinib, and Dasatinib work by specifically targeting the tyrosine kinase domain of their respective receptors or non-receptor tyrosine kinases, potentially leading to reduced C1orf50_AU022252activity if its function is modulated by tyrosine kinase pathways. Similarly, by targeting PI3K/Akt and mTOR pathways, LY 294002, Wortmannin, and Rapamycin may decrease the activity of C1orf50_AU022252 if it is a downstream target or is regulated by these pathways. The inhibition of mTOR by Rapamycin is particularly critical because of its central role in cell growth and metabolism, which may indirectly affect the functional state of C1orf50_AU022252.
Inhibitors that disrupt MAPK signaling, such as PD 98059, U0126, SB 203580, and SP600125, could also lead to reduced activity of C1orf50_AU022252 if its activity is modulated by ERK, p38, or JNK pathways. PD 98059 and U0126 specifically inhibit MEK1/2, thereby potentially diminishing ERK pathway signaling, which may be a regulatory factor for C1orf50_AU022252. SB203580's inhibition of p38 MAPK and SP600125's targeting of JNK pathways further expand the range of potential indirect inhibition mechanisms. Such a diverse spectrum of inhibitors reflects the complex regulatory networks that can govern protein function, with each inhibitor providing a unique angle of interference with C1orf50_AU022252's activity, emphasizing the multifaceted nature of cellular signaling and the various points at which it can be attenuated to influence the function of specific proteins.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
As a potent inhibitor of protein kinases, Staurosporine indirectly inhibits C1orf50_AU022252 by inhibiting kinases that phosphorylate proteins downstream or upstream of C1orf50_AU022252, thus negatively affecting its functional activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A phosphatidylinositol 3-kinase (PI3K) inhibitor, LY 294002, diminishes the PI3K/AKT pathway activity. Since AKT can phosphorylate various proteins that interact with or regulate C1orf50_AU022252, inhibition by LY 294002 would result in a decreased regulation of C1orf50_AU022252 activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
As an mTOR inhibitor, Rapamycin decreases the activity of the mTOR pathway, which is involved in protein synthesis and autophagy. The inhibition of this pathway can indirectly diminish the functional activity of C1orf50_AU022252 if it is a downstream effector of mTOR signaling. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
As a specific inhibitor of MEK1, PD 98059 indirectly diminishes the MAPK/ERK pathway. If C1orf50_AU022252 activity is regulated by ERK-mediated phosphorylation, this inhibition would result in a reduced functional activity of C1orf50_AU022252. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
A selective inhibitor of p38 MAPK, SB 203580, reduces the activity of the p38 MAPK signaling pathway. If C1orf50_AU022252 functions in a pathway downstream of p38 MAPK, its activity would be indirectly diminished. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent inhibitor of PI3K. Its inhibition of the PI3K/AKT pathway could lead to a reduction in the functional activity of C1orf50_AU022252 if it is regulated by PI3K signaling. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of c-Jun N-terminal kinase (JNK), SP600125, would lead to the diminished functional activity of C1orf50_AU022252 if it is part of the JNK signaling pathway or if JNK phosphorylates proteins that affect C1orf50_AU022252 activity. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
As an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, Gefitinib could diminish C1orf50_AU022252 activity if C1orf50_AU022252 is part of the EGFR signaling pathway or if EGFR-mediated signaling events regulate its activity. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
A tyrosine kinase inhibitor, Imatinib, could indirectly inhibit C1orf50_AU022252 by blocking signaling pathways that involve tyrosine kinases which, when active, enhance the functional activity of C1orf50_AU022252. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
As a broad-spectrum tyrosine kinase inhibitor, Dasatinib could diminish the activity of C1orf50_AU022252 by inhibiting kinases that would typically phosphorylate and activate proteins that modulate C1orf50_AU022252 activity. | ||||||